Adaptive biotechnologies stock.

SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...

Adaptive biotechnologies stock. Things To Know About Adaptive biotechnologies stock.

Discover historical prices for ADPT stock on Yahoo Finance. View daily, weekly or monthly format back to when Adaptive Biotechnologies Corporation stock was issued.Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 13.51% and 0.31%, ... Do the numbers hold clues to what lies ahead for the stock? Adaptive Biotechnologies ...SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical ...The institutional investor acquired 53,400 shares of the company’s stock, corresponding to a value of approximately $472,000. Adaptive Biotechnologies Co., listed on NASDAQ under the symbol ADPT, opened at $6.17 on Tuesday. Over the past year, its stock has ranged between a low of $5.96 and a high of $10.79.

Watch Adaptive Biotechnologies stock price move in real-time ahead here. On February 14, Adaptive Biotechnologies will release earnings for the most recent quarter.

SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth …Adaptive Biotechnologies Corporation has completed an IPO in the amount of $300 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,000,000 PriceRange: $20 Discount Per Security: $1.4 Transaction Features: Reserved Share Offering; Sponsor Backed Offering

Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third ...Adaptive Biotechnologies. Wood has bought almost 10 million shares of this stock for her ARK Genomic Revolution fund. Adaptive Biotechnologies Corp. ( NASDAQ: ADPT ) is a commercial-stage company ...Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the ...Stock. Stock Quote & Chart ... Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetic language of the adaptive immune ...

Adaptive Biotechnologies Corporation announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease using clonoSEQ assay technology across the company's... 9db0a67e808.iuF5UsgyO_ajPyA0evrp3ms_tEK0Phtld4MZtKLQRYA.s5AxE5BLZIyTRkdbAM_RlAUMgiTSCiwVG9Z-g9qmC-LO2DMmgwtVt-VZbQ

Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating. Oct. 24. MT. BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating. Oct. 20.

Meet Adaptive. The adaptive immune system is a force inside your body so powerful it’s able to detect disease and fight it, often before you even realize that you’re sick. Adaptive Biotechnologies is harnessing this vast system of biology to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine. Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. 11-02-2023 at 4:07 PM EDT. Adaptive Announces Launch of Epic Integration for clonoSEQ®. 09-13-2023 at 7:31 AM EDT. Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference. 08-30-2023 at 4:30 PM EDT.Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to …Dec 1, 2023 · Adaptive Biotechnologies - ADPT - Stock Price Today - Zacks Adaptive Biotechnologies (ADPT) (Delayed Data from NSDQ) $4.37 USD +0.12 (2.82%) Updated Nov 24, 2023 12:59 PM ET After-Market:... SEATTLE, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the commencement of a proposed underwritten public offering …Get the latest Adaptive Biotechnologies Corporation (ADPT) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Interested individuals can access further details through the hyperlink provided by Adaptive Biotechnologies. Overall insider trading activity for Adaptive Biotechnologies has been noteworthy, with insiders recently selling 242,961 shares of the company’s stock. These transactions have amounted to a total value of $1,967,763.

SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth …Adaptive Biotechnologies Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) ... Preferred stock: $0.0001 par value, 10,000,000 shares authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 2021 ...Adaptive Biotechnologies Corporation announces a multi-year collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ® assay technology across the company’s pipeline of treatments for patients with lymphoid malignancies. This collaboration aims to support the clinical development and potential …Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the ...SEATTLE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY.Get the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. See the performance outlook, earnings date, dividend yield, research reports and more for ADPT …

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies Corporation will report financial results for Q3 2023 on November 9, 2023. The company aims to translate the genetics of t...Oct 17, 2023 · The latest Adaptive Biotechnologies Corporation Registered Shs stock prices, stock quotes, news, and ADPT history to help you invest and trade smarter. Jun 2, 2023 · SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical ... Nov 22, 2023 · In summary, Adaptive Biotechnologies Corp (ADPT) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high. Whatever you make of her stock choices, Woo. ... Adaptive Biotechnologies is a pioneering commercial-stage biotech company at the forefront of immune-driven medicine. By harnessing genetic data ...SEATTLE, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...View the latest Adaptive Biotechnologies Corp. (ADPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Watch Adaptive Biotechnologies stock price move in real-time ahead here. On February 14, Adaptive Biotechnologies will release earnings for the most recent quarter.

The growth-stock investor added to her stakes in UiPath (PATH 26.72%), Prime Medicine (PRME 11.02%), and Adaptive Biotechnologies (ADPT 7.31%) on Thursday. What does Wood see in these three ...

Sep 30, 2022 · 2022 Financial Guidance. Adaptive Biotechnologies narrows full year 2022 revenue to be in the range of $185 million to $190 million compared to the previous expectation of $185 million to $195 million. We now expect full year 2022 operating expenses to be below $400 million compared to the previous expectation of between $410 million and $415 ... Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...Biotechnology is a rapidly evolving field that combines biology and technology to develop innovative solutions for various industries. Pursuing a B Tech in Biotechnology can open up exciting career opportunities in research, healthcare, agr...Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s traded shares stood at 0.53 million during the last session, with the company’s beta value hitting 1.21. At the close of trading, the stock’s price was $4.21, to imply a decrease of -0.94% or -$0.04 in intraday trading. The ADPT share’s 52-week ...Adaptive Biotechnologies Corp. Watch NEW Set a price target alert After Hours Last Updated: Nov 24, 2023 4:51 p.m. EST Delayed quote $ 4.2000 -0.17 -3.89% After Hours Volume: 4.47K Advanced... This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or …ADPT Earnings Date and Information. Adaptive Biotechnologies last announced its earnings data on November 9th, 2023. The reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.03. The business earned $37.92 million during the quarter, compared to analyst estimates of $43.26 million.Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system to facilitate the diagnosis and treatment of disease. Its clinical diagnostic ...

If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Mar 24, 2023 · As of March 24, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.43. Adaptive Biotechnologies Corp is up 7.53% from its previous closing price of $7.84. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.79 and $8.24. Currently, there are 143.06 million shares of Adaptive ... Nov 9, 2023 · Adaptive’s net loss came in at $50.3 million, compared to $45.3 million in the same period last year. The company’s stock dipped nearly 5% today. Adaptive Biotechnologies hired Goldman Sachs ... Instagram:https://instagram. f x ybest dental insurance in ga no waiting perioddividend yield on sandp 500wcda loan How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding.Dec 1, 2023 · Adaptive Biotechnologies - ADPT - Stock Price Today - Zacks Adaptive Biotechnologies (ADPT) (Delayed Data from NSDQ) $4.37 USD +0.12 (2.82%) Updated Nov 24, 2023 12:59 PM ET After-Market:... mt4 futures brokersmy car was vandalized will insurance cover it Adaptive Biotechnologies Corporation will report financial results for Q3 2023 on November 9, 2023. The company aims to translate the genetics of t... how can i buy hong kong stocks Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system to facilitate the diagnosis and treatment of disease. Its clinical diagnostic ...Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. 11-02-2023 at 4:07 PM EDT. Adaptive Announces Launch of Epic Integration for clonoSEQ®. 09-13-2023 at 7:31 AM EDT. Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference. 08-30-2023 at 4:30 PM EDT.Piper Sandler has a $15 target price for Adaptive Biotechnologies stock. The consensus target is $12.29, and shares closed on Friday at $7.46, which was up almost 6% for the day.